

JUBILANT BIOSYS (SINGAPORE) PTE LTD

Balance Sheet

As at 31 March	Notes No	2016 USD	2016 INR (' In Thousands)	2015 USD	2015 INR (' In Thousands)
<b>I. EQUITY AND LIABILITIES</b>					
<b>Shareholders' Funds</b>					
Share capital	1	13,71,501	68,559	13,71,501	68,559
Reserves and surplus	2	-86,255	16,588	-74,344	12,513
		12,85,246	85,147	12,97,157	81,072
<b>Current liabilities</b>					
Trade payables	3	27,610	1,829	13,848	865
Other current liabilities	4	159	11	159	11
		27,769	1,840	14,006	876
	<b>Total</b>	<b>13,13,015</b>	<b>86,987</b>	<b>13,11,163</b>	<b>81,948</b>
<b>II. ASSETS</b>					
<b>Non-current investments</b>					
Non-current investments	5	13,06,552	86,559	13,06,552	81,660
<b>Long-term loans and advances</b>					
Long-term loans and advances	6	3,720	246	3,636	227
		13,10,272	86,805	13,10,188	81,887
<b>Current assets</b>					
Cash and bank balances	7	975	65	975	61
Short-term loans and advances	8	1,768	117	0	0
		2,743	182	975	61
	<b>Total</b>	<b>13,13,015</b>	<b>86,987</b>	<b>13,11,163</b>	<b>81,948</b>

Prakash C Bisht  
CFO ( Ingredients ) & Sr. VP ( Group Accounts )  
Place : Noida  
Date : 23 May 2016

Jub Biosys(Singapore)Pte Ltd

Cash flow Statement for the Year Ended 31 March

Particulars	2016		2015	
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
<b>Cash flows from operating activities</b>				
Net Loss before tax	(11,911)	(777)	(13,169)	(805)
<b>Operating profit before working capital changes</b>	<b>(11,911)</b>	<b>(777)</b>	<b>(13,169)</b>	<b>(805)</b>
Adjustments for :				
(Increase)/Decrease in trade and other receivables	(1,852)	(121)	335	20
Increase in trade and other payables	13,763	898	9,125	58
<b>A. Net cash inflow/(outflow) in course of operating activities</b>	<b>-</b>	<b>-</b>	<b>(3,709)</b>	<b>(227)</b>
<b>B. Foreign currency translation difference arising on consolidation</b>		4		7
<b>Net Increase in cash and cash equivalents (A+B)</b>	<b>-</b>	<b>4</b>	<b>(3,708)</b>	<b>(220)</b>
Add: cash and cash equivalents at the beginning of year	975	61	4,683	281
<b>Cash and cash equivalents at the close of the year</b>	<b>975</b>	<b>65</b>	<b>975</b>	<b>61</b>

Notes:

1) cash Flow Statement has been prepared under the direct method as set out in Accounting Standard 3(AS-)-" Cash Flow Statements"

Prakash C Bisht  
 CFO ( Ingredients) & Sr. VP (Group Accounts)  
 Place : Noida  
 Date : 23 May 2016

JUBILANT BIOSYS (SINGAPORE) PTE LTD  
Notes to the Financial Statements

As at 31 March	2016	2016	2015	2015
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
<b>1. SHARE CAPITAL</b>				
Issued and Subscribed				
1,371,501 equity shares of USD 1 each (Previous Year 1,371,501 equity shares of USD 1 each)	13,71,501	68,559	13,71,501	68,559
	13,71,501	68,559	13,71,501	68,559
Paid up				
1,371,501 equity shares of USD 1 each (Previous Year 1,371,501 equity shares of USD 1 each)	13,71,501	68,559	13,71,501	68,559
	-	-	-	-
	13,71,501	68,559	13,71,501	68,559

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shareholders holding more than 5% shares as at 31 March, 2016 and 31 March 2015 is set out below:

As at 31 March	2016	2016	2015	2015
Name of the shareholder	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Jubilant Biosys (BVI) LTD , BRITISH VIRGIN ISLANDS-The Holding Company	13,71,501	100.00%	13,71,501	100.00%

4) The reconciliation of the number of shares outstanding as at 31 March, 2016 and 31 March, 2015 is set out below:

As at 31 March	2016	2016	2015	2015
Name of the shareholder	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Numbers of shares at the beginning	13,71,501	68,559	13,56,501	67,722
Add: Shares issued during the year	-	-	15,000.00	837
Numbers of shares at the end	13,71,501	68,559	13,71,501	68,559

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31 March	2016	2016	2015	2015
Particulars	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company 1,371,501 equity shares of USD 1 each	13,71,501	68,559	13,71,501	68,559

JUBILANT BIOSYS (SINGAPORE) PTE LTD

Notes to the Financial Statements

As at 31 March	2016	2016	2015	2015
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
<b>2. RESERVES AND SURPLUS</b>				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	16,431	-	-
Foreign Currency Translation Reserve During the Year	-	4,846	-	16,431
	-	21,277	-	16,431
Surplus as per P&L Account				
As per last Balance Sheet	-74,344	-3,918	-61,175	-3,113
Add: Net Profit after tax transferred from Statement of Profit and Loss	-11,911	-771	-13,169	-805
	-86,255	-4,689	-74,344	-3,918
	-86,255	16,588	-74,344	12,513
<b>3. TRADE PAYABLES</b>				
Trade payables-others	27,610	1,829	13,848	865
	27,610	1,829	13,848	865
<b>4. OTHER CURRENT LIABILITIES</b>				
Other payables	159	11	159	10
	159	11	159	10
<b>5. NON CURRENT INVESTMENTS</b>				
Investment in Subsidiary/Fellow Subsidiaries Companies				
Jubilant Biosys LTD	13,06,552	86,559	13,06,552	81,660
295600 shares of USD 10 each	13,06,552	86,559	13,06,552	81,660
<b>6. LONG TERM LOAN AND ADVANCES</b>				
	3,720	246	3,636	227
	3,720	246	3,636	227
<b>7. CASH AND BANK BALANCES</b>				
Balances with banks:				
- On current accounts	975	65	975	61
	2,743	182	975	61
<b>8. SHORT TERM LOAN AND ADVANCES</b>				
Prepaid Expenses	1,768	117	0	0
	1,768	117	0	0
<b>9. OTHER EXPENSE</b>				
Auditors Remuneration - As Auditors	4,002	262	4,016	245
Legal , professional and consultancy charges	7,993	515	8,798	538
Bank Charges	-	-	20	1
	11,995	777	12,834	784
<b>10. EXCEPTIONAL ITEMS</b>				
Foreign Exchange Gain/Loss	-84	-6	335	21
	-84	-6	335	21